16454
2016
eng
936
16
article
1
2018-07-16
--
--
Tumour stage distribution and survival of malignant melanoma in Germany 2002-2011
Background
Over the past two decades, there has been a rising trend in malignant melanoma incidence worldwide. In 2008, Germany introduced a nationwide skin cancer screening program starting at age 35. The aims of this study were to analyse the distribution of malignant melanoma tumour stages over time, as well as demographic and regional differences in stage distribution and survival of melanoma patients.
Methods
Pooled data from 61 895 malignant melanoma patients diagnosed between 2002 and 2011 and documented in 28 German population-based and hospital-based clinical cancer registries were analysed using descriptive methods, joinpoint regression, logistic regression and relative survival.
Results
The number of annually documented cases increased by 53.2% between 2002 (N = 4 779) and 2011 (N = 7 320). There was a statistically significant continuous positive trend in the proportion of stage UICC I cases diagnosed between 2002 and 2011, compared to a negative trend for stage UICC II. No trends were found for stages UICC III and IV respectively. Age (OR 0.97, 95% CI 0.97–0.97), sex (OR 1.18, 95% CI 1.11–1.25), date of diagnosis (OR 1.05, 95% CI 1.04–1.06), ‘diagnosis during screening’ (OR 3.24, 95% CI 2.50–4.19) and place of residence (OR 1.23, 95% CI 1.16–1.30) had a statistically significant influence on the tumour stage at diagnosis. The overall 5-year relative survival for invasive cases was 83.4% (95% CI 82.8–83.9%).
Conclusions
No distinct changes in the distribution of malignant melanoma tumour stages among those aged 35 and older were seen that could be directly attributed to the introduction of skin cancer screening in 2008.
"
BMC Cancer
10.1186/s12885-016-2963-0
urn:nbn:de:bvb:20-opus-164544
BMC Cancer (2016) 16:936
false
true
CC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International
Olaf Schoffer
Stefanie Schülein
Gerlinde Arand
Hans Arnholdt
Dieter Baaske
Ralf C. Bargou
Nikolaus Becker
Matthias W. Beckmann
Yves Bodack
Beatrix Böhme
Tayfun Bozkurt
Regine Breitsprecher
Andre Buchali
Elke Burger
Ulrike Burger
Klaus Dommisch
Gudrun Elsner
Karin Fernschild
Ulrike Flintzer
Uwe Funke
Michael Gerken
Hubert Göbel
Norbert Grobe
Vera Gumpp
Lucie Heinzerling
Lana Raffaela Kempfer
Alexander Kiani
Monika Klinkhammer-Schalke
Sabine Klöcking
Ute Kreibich
Katrin Knabner
Peter Kuhn
Stine Lutze
Uwe Mäder
Tanja Maisel
Jan Maschke
Martin Middeke
Andreas Neubauer
Antje Niedostatek
Anabelle Opazo-Saez
Christoph Peters
Beatrice Schell
Gerhard Schenkirsch
Harald Schmalenberg
Peter Schmidt
Constanze Schneider
Birgit Schubotz
Anika Seide
Paul Strecker
Sabine Taubenheim
Matthias Wackes
Steffen Weiß
Claudia Welke
Carmen Werner
Christian Wittekind
Jörg Wulff
Heike Zettl
Stefanie J. Klug
eng
uncontrolled
Malignant melanoma
eng
uncontrolled
TNM staging
eng
uncontrolled
Survival analysis
eng
uncontrolled
Skin cancer screening
eng
uncontrolled
Stage distribution
Medizin und Gesundheit
open_access
Medizinische Klinik und Poliklinik II
Universität Würzburg
https://opus.bibliothek.uni-wuerzburg.de/files/16454/013_Schoffer_BMC-CANCER.pdf
22628
2018
eng
266-271
4
18
article
1
2021-02-23
--
--
Effect of ABCG2, OCT1, and ABCB1 (MDR1) Gene Expression on Treatment-Free Remission in a EURO-SKI Subtrial
Within the EURO-SKI trial, 132 chronic phase CML patients discontinued imatinib treatment. RNA was isolated from peripheral blood in order to analyze the expression of MDR1, ABCG2 and OCT1. ABCG2 was predictive for treatment-free remission in Cox regression analysis. High transcript levels of the ABCG2 efflux transporter (>4.5 parts per thousand) were associated with a twofold higher risk of relapse. Introduction: Tyrosine kinase inhibitors (TKIs) can safely be discontinued in chronic myeloid leukemia (CML) patients with sustained deep molecular response. ABCG2 (breast cancer resistance protein), OCT1 (organic cation transporter 1), and ABCB1 (multidrug resistance protein 1) gene products are known to play a crucial role in acquired pharmacogenetic TKI resistance. Their influence on treatment-free remission (TFR) has not yet been investigated. Materials and Methods: RNA was isolated on the last day of TKI intake from peripheral blood leukocytes of 132 chronic phase CML patients who discontinued TKI treatment within the European Stop Tyrosine Kinase Inhibitor Study trial. Plasmid standards were designed including subgenic inserts of OCT1, ABCG2, and ABCB1 together with GUSB as reference gene. For expression analyses, quantitative real-time polymerase chain reaction was used. Multiple Cox regression analysis was performed. In addition, gene expression cutoffs for patient risk stratification were investigated. Results: The TFR rate of 132 patients, 12 months after TKI discontinuation, was 54% (95% confidence interval [CI], 46%-62%). ABCG2 expression (parts per thousand) was retained as the only significant variable (P=.02; hazard ratio, 1.04; 95% CI, 1.01-1.07) in multiple Cox regression analysis. Only for the ABCG2 efflux transporter, a significant cutoff was found (P=.04). Patients with an ABCG2/GUSB transcript level >4.5 parts per thousand (n=93) showed a 12-month TFR rate of 47% (95% CI, 37%-57%), whereas patients with low ABCG2 expression (<= 4.5 parts per thousand; n=39) had a 12-month TFR rate of 72% (95% CI, 55%-82%). Conclusion: In this study, we investigated the effect of pharmacogenetics in the context of a CML treatment discontinuation trial. The transcript levels of the efflux transporter ABCG2 predicted TFR after TKI discontinuation. (C) 2018 The Authors. Published by Elsevier Inc.
Clinical Lymphoma, Myeloma & Leukemia
10.1016/j.clml.2018.02.004
urn:nbn:de:bvb:20-opus-226281
publish
Clinical Lymphoma, Myeloma & Leukemia, Vol. 18, No. 4, 266-71
true
true
CC BY-NC-ND: Creative-Commons-Lizenz: Namensnennung, Nicht kommerziell, Keine Bearbeitungen 4.0 International
Sébastien Rinaldetti
Markus Pfirrmann
Kirsi Manz
Joelle Guilhot
Christian Dietz
Panayiotidis Panagiotidis
Birgit Spiess
Wolfgang Seifarth
Alice Fabarius
Martin Müller
Maria Pagoni
Maria Dimou
Jolanta Dengler
Cornelius F. Waller
Tim H. Brümmendorf
Regina Herbst
Andreas Burchert
Carsten Janßen
Maria Elisabeth Goebeler
Philipp J. Jost
Stefan Hanzel
Philippe Schafhausen
Gabriele Prange-Krex
Thomas Illmer
Viktor Janzen
Martine Klausmann
Robert Eckert
Gerd Büschel
Alexander Kiani
Wolf-Karsten Hofmann
François-Xavier Mahon
Susanne Saussele
eng
uncontrolled
ABCG2
eng
uncontrolled
Biomarker
eng
uncontrolled
CML
eng
uncontrolled
Imatinib
eng
uncontrolled
Prediction
Medizin und Gesundheit
open_access
Medizinische Klinik und Poliklinik II
Universität Würzburg
https://opus.bibliothek.uni-wuerzburg.de/files/22628/Effect_of_ABCG2.pdf